Table 1 Patient characteristics and treatments
MPA | GPA | |
|---|---|---|
(n = 78) | (n = 33) | |
Age (years), mean ± SD | 71 ± 10 | 64 ± 13 |
Sex (male:female) | 35:43 | 12:21 |
Disease severity, n | ||
Limited | 0 | 4 |
Early systemic | 15 | 5 |
General | 47 | 18 |
Severe | 16 | 6 |
MPO-ANCA, n (%) | 76 (97) | 18 (55) |
PR3-ANCA, n (%) | 2 (3) | 15 (46) |
Serum creatinine (mg/dl), mean ± SD | 2.46 ± 2.18 | 1.51 ± 1.32 |
BVAS, mean ± SD | 18 ± 7 | 20 ± 7 |
Initial treatments (within 3 weeks) | ||
Maximum daily dose of PSL (mg/day), mean ± SD | 41 ± 15 | 40 ± 15 |
mPSL pulse use, n (%) | 34 (44) | 13 (39) |
Cyclophosphamide, n (%) | 24 (31) | 20 (60) |
Oral:intravenous | 3:21 | 7:13 |
Cumulative dose for 6 months (g), mean ± SD | 2.6 ± 2.8 | 4.3 ± 3.6 |
Methotrexate, n (%) | 0 (0) | 2 (6) |
Azathioprine, n (%) | 0 (0) | 0 (0) |
Treatments at 6 months | ||
n = 62 | n = 30 | |
Minimum daily dose of PSL (mg/day), mean ± SD | 12 ± 5 | 13 ± 6 |
Cyclophosphamide, n | 20 | 16 |
Methotrexate, n | 0 | 3 |
Azathioprine, n | 10 | 8 |
Treatments at 12 months | ||
n = 56 | n = 28 | |
Minimum daily dose of PSL (mg/day), mean ± SD | 9 ± 5 | 9 ± 6 |
Cyclophosphamide, n | 9 | 7 |
Methotrexate, n | 0 | 4 |
Azathioprine, n | 11 | 11 |
Treatments at 24 months | ||
n = 52 | n = 28 | |
Minimum daily dose of PSL (mg/day), mean ± SD | 7 ± 5 | 6 ± 3 |
Cyclophosphamide, n | 4 | 5 |
Methotrexate, n | 0 | 4 |
Azathioprine, n | 10 | 5 |